Last reviewed · How we verify

Pramlintide + Insulin — Competitive Intelligence Brief

Pramlintide + Insulin (Pramlintide + Insulin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Amylin analog + Insulin combination. Area: Diabetes.

marketed Amylin analog + Insulin combination Amylin receptor (pramlintide component); Insulin receptor (insulin component) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Pramlintide + Insulin (Pramlintide + Insulin) — Montefiore Medical Center. Pramlintide slows gastric emptying and suppresses glucagon secretion, while insulin lowers blood glucose, together improving postprandial glucose control in diabetes.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pramlintide + Insulin TARGET Pramlintide + Insulin Montefiore Medical Center marketed Amylin analog + Insulin combination Amylin receptor (pramlintide component); Insulin receptor (insulin component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Amylin analog + Insulin combination class)

  1. Montefiore Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pramlintide + Insulin — Competitive Intelligence Brief. https://druglandscape.com/ci/pramlintide-insulin. Accessed 2026-05-21.

Build your own brief

Pick any drug + add comparators: